SCYNEXIS to Execute 1-for-8 Reverse Stock Split to Regain Nasdaq Compliance
SCYX sits 20% above its 52-week low of $0.565.
Summary
SCYNEXIS announced a 1-for-8 reverse stock split, effective May 29, 2026, with trading on a split-adjusted basis starting June 1. This follows shareholder approval on May 19, as outlined in previous proxy filings. The primary goal is to regain compliance with Nasdaq's minimum bid price requirement, reducing outstanding shares from approximately 79.5 million to 9.9 million. While crucial for continued listing, reverse splits are generally perceived negatively by the market, often indicating a company's struggle to maintain its stock price and potentially signaling underlying financial distress.
At the time of this announcement, SCYX was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $58.1M. The 52-week trading range was $0.57 to $1.31. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.